The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Emerging therapies in MCL: the promise of immunotherapies
Jia Ruan, MD, PhD, Weill Cornell Medicine, New York, NY, discusses emerging therapies in mantle cell lymphoma (MCL), drawing focus on the role of immunotherapies. Dr Ruan first highlights the promise of CAR-T cell therapy, and then goes on to comment on the promise of reversible BTK inhibitors, such as pirtobrutinib. Following this, Dr Ruan discusses the potential role of bispecific antibodies in MCL, and further summarizes ongoing clinical trials in this space, as well as the importance of bringing novel agents into earlier lines of therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
